<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934059</url>
  </required_header>
  <id_info>
    <org_study_id>2020005P8A02</org_study_id>
    <nct_id>NCT04934059</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS).</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to&#xD;
      evaluate the efficacy and safety of Yuxuebi tablet in treating night pain of Ankylosing&#xD;
      Spondylitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual analogue scale (VAS) for night pain</measure>
    <time_frame>Baseline, at day 7, day 14, day 28, day 42 during treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS) for whole day</measure>
    <time_frame>Baseline, at day 7, day 14, day 28, day 42 during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)</measure>
    <time_frame>Baseline, at day 28, day 42 during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BASFI (Bath Ankylosing Spondylitis Functional Index)</measure>
    <time_frame>Baseline, at day 28, day 42 during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BASMI (Bath Ankylosing Spondylitis Metrology Index)</measure>
    <time_frame>Baseline, at day 28, day 42 during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Syndrome score of traditional Chinese medicine</measure>
    <time_frame>Baseline, at day 28, day 42 during treatment</time_frame>
    <description>The Evaluation Scale of Syndrome score ranges from 0 (best score) to 15 (worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 (The Medical Outcomes Study 36-item short-form health survey)</measure>
    <time_frame>Baseline, at day 42 during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESR (Erythrocyte Sedimentation Rate)</measure>
    <time_frame>Baseline, at day 14, day 28, day 42 during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP (C-Reactive Protein)</measure>
    <time_frame>Baseline, at day 14, day 28, day 42 during treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Yuxuebi tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take 5 tablets once, 3 times a day, for 42（±3）days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>take 5 tablets once, 3 times a day, for 42（±3）days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yuxuebi tablet</intervention_name>
    <description>0.5g/ tablet</description>
    <arm_group_label>Yuxuebi tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>0.5g/ tablet</description>
    <arm_group_label>Placebo tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 18-65, male or female&#xD;
&#xD;
          2. Confirmed diagnosis of Ankylosing Spondylitis&#xD;
&#xD;
          3. Syndrome of traditional Chinese medicine is blood stasis syndrome&#xD;
&#xD;
          4. ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score)≥2.1&#xD;
&#xD;
          5. Visual analogue scale (VAS) for night pain≥4分&#xD;
&#xD;
          6. Maintained stable doses of Sulfasalazine, Methotrexate, Leflunomide, etc. for more&#xD;
             than 1 month if treating with Slow-Acting Antirheumatic Drugs&#xD;
&#xD;
          7. Maintained stable doses of biologics for more than 3 month if treating with biologics&#xD;
&#xD;
          8. Not use Nonsteroidal Antiinflammatory Drugs within 2 weeks&#xD;
&#xD;
          9. Patients who have not participated in other clinical trials within 4 weeks&#xD;
&#xD;
         10. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding or who expecting to conceive&#xD;
&#xD;
          2. Psoriatic arthritis or Enteropathic arthritis&#xD;
&#xD;
          3. AS with iritis or uveitis&#xD;
&#xD;
          4. Abnormal liver function&#xD;
&#xD;
          5. Abnormal kidney function，high level of Creatinine&#xD;
&#xD;
          6. WBC (White Blood Cell)&lt;3.0×10^9/L or with Hematological Disease&#xD;
&#xD;
          7. Patients with poor control of hypertension or diabetes&#xD;
&#xD;
          8. Acute or chronic infectious diseases&#xD;
&#xD;
          9. Severe arrhythmia&#xD;
&#xD;
         10. Patients with malignant tumors or with a history of malignant tumors&#xD;
&#xD;
         11. Drug allergy&#xD;
&#xD;
         12. Patients who had taken Yuxuebi tablet for more than 4 weeks with poor outcome&#xD;
&#xD;
         13. Patients who are treating with Traditional Chinese medicine for promoting blood&#xD;
             circulation and removing blood stasis&#xD;
&#xD;
         14. Alcohol or drug abuse&#xD;
&#xD;
         15. Participants who are not suitable for clinical trial under doctors' consideration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guang'anmen Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Quan Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaoyan Cai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Jinzhong</name>
      <address>
        <city>Jinzhong</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tao Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanchong Central Hospital</name>
      <address>
        <city>Nanchong</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shiquan Shuai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Traditional Chinese Medicine Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianyong Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

